# 04_QA_REPORT.md

# Quality Assurance Report

## Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0226 |
| Population Package ID | PP-0226 |
| Title | HIPEC |
| Version | 1.0.0 |
| Status | PASS — GOLD |
| QA Mode | Four-layer substantive QA |
| Source-First | PASS |
| Locked Decision Integrity | PASS |

---

# Executive QA Decision

## Final Decision

# PASS — GOLD

The PP-0226 package is consistent with the approved and locked Decision Batch.

The package preserves:

- atomic treatment-modality ownership;
- Source-First evidence use;
- current NCCN positioning;
- evidence heterogeneity;
- patient-facing depth;
- Knowledge Graph relationships;
- adjacent PP boundaries;
- safety constraints;
- Gold artifact structure.

No material blocker was identified.

---

# Layer 1 — Content QA

## 1. Scope Compliance

### Requirement

PP-0226 must answer one atomic clinical educational question about HIPEC.

### Assessment

**PASS**

The package owns:

- HIPEC definition;
- rationale;
- relationship with cytoreductive surgery;
- selected-use pathway;
- evidence;
- risks;
- uncertainty;
- patient-facing interpretation.

It does not absorb the broader peritoneal-disease pathway.

---

## 2. Completeness

### Required domains

- definition;
- rationale;
- selection;
- PCI;
- complete cytoreduction;
- evidence;
- safety;
- uncertainty;
- patient questions;
- boundary;
- Knowledge Graph.

### Assessment

**PASS**

All required domains are represented.

---

## 3. Atomicity

### Test

Does PP-0226 answer one clinical educational question?

### Assessment

**PASS**

The package is treatment-modality-specific.

It does not become:

- a metastatic gastric cancer overview;
- a peritoneal carcinomatosis package;
- a surgical technique package;
- a systemic-therapy package.

---

## 4. Internal Consistency

The following statements remain consistent throughout:

- HIPEC is selected, not universal.
- HIPEC is linked to cytoreductive surgery.
- PCI is important but not sufficient alone.
- complete cytoreduction is important.
- multidisciplinary review is required.
- evidence is heterogeneous.
- GASTRIPEC-I did not demonstrate statistically significant OS benefit.
- PIPAC remains investigational in the supplied NCCN framework.

### Assessment

**PASS**

---

# Layer 2 — Clinical QA

## 5. Guideline Alignment

### Primary authority

NCCN Gastric Cancer v2.2026.

### Verification

The package accurately preserves the guideline concepts:

- selected IC/HIPEC use;
- multidisciplinary discussion;
- pretreatment evaluation;
- systemic therapy before reassessment;
- PCI ≤10 selected option;
- complete-cytoreduction requirement;
- PCI >10 clinical-trial context;
- PIPAC investigational.

### Assessment

**PASS**

---

## 6. Clinical Safety

### Potential safety risk

A patient may interpret PCI ≤10 as automatic eligibility.

### Safeguard present

The package explicitly states:

> PCI ≤10 does not mean automatic HIPEC.

It requires context including:

- disease control;
- extraperitoneal disease;
- complete cytoreduction;
- multidisciplinary assessment;
- patient fitness.

### Assessment

**PASS**

---

## 7. No Individualized Treatment Advice

The package does not:

- prescribe HIPEC;
- calculate eligibility;
- provide individualized prognosis;
- instruct a patient to change treatment.

### Assessment

**PASS**

---

## 8. Evidence Interpretation Safety

The package distinguishes:

- propensity-score evidence;
- randomized evidence;
- ongoing evidence.

### Assessment

**PASS**

---

## 9. Endpoint Interpretation

The package does not conflate:

- OS;
- PFS;
- recurrence-free survival;
- distant-metastasis-free survival.

GASTRIPEC-I is explicitly presented as:

- no statistically significant OS benefit;
- PFS improvement;
- other distant-metastasis-free survival improvement.

### Assessment

**PASS**

---

## 10. Morbidity Interpretation

The 70% morbidity figure is labeled as:

- from a specific phase II cohort;
- n=20;
- combined major treatment.

It is not presented as a universal HIPEC risk.

### Assessment

**PASS**

---

## 11. Mortality Interpretation

The 0% 90-day mortality from the phase II study is clearly treated as study-specific.

### Assessment

**PASS**

---

# Layer 3 — Educational QA

## 12. Patient-Facing Explanation

The CKO explains:

- what HIPEC is;
- why it is considered;
- why selection matters;
- why PCI matters;
- why surgery matters;
- what the evidence says;
- what uncertainty remains.

### Assessment

**PASS**

---

## 13. Terminology

Technical terms are introduced with explanations:

- HIPEC;
- PCI;
- cytoreductive surgery;
- extraperitoneal disease;
- PIPAC;
- complete cytoreduction.

### Assessment

**PASS**

---

## 14. Misconception Control

The package includes explicit myths/facts covering:

- universal HIPEC;
- PCI threshold;
- cure;
- systemic therapy replacement;
- CYTO-CHIP interpretation;
- morbidity;
- PIPAC;
- complete cytoreduction.

### Assessment

**PASS**

---

## 15. Logical Flow

The educational progression is:

**Definition**

→ **Rationale**

→ **Surgical relationship**

→ **Selection**

→ **PCI**

→ **Evidence**

→ **Safety**

→ **Uncertainty**

→ **Patient questions**

This matches the intended patient journey.

### Assessment

**PASS**

---

# Layer 4 — Governance QA

## 16. Source-First Audit

### Required

PP-specific clinical materials must be searched before generic knowledge.

### Evidence used

The supplied NCCN Gastric Cancer v2.2026 and v2.2025 materials were searched and used as the primary clinical basis.

### Assessment

**PASS**

---

## 17. Gold Template Adherence

### Required

Gold structure and depth must be preserved.

### Assessment

The four artifacts contain:

- CKO;
- Knowledge Passport;
- Primary Evidence Package;
- QA Report.

The package preserves:

- clinical reasoning;
- patient-facing explanation;
- evidence traceability;
- Knowledge Graph;
- safety;
- boundary;
- QA depth.

### Assessment

**PASS**

---

## 18. Gold Depth Integrity

### Rule

Gold depth is a minimum standard.

The package must not be materially shortened, compacted, summarized, or reduced relative to approved Gold references.

### Assessment

**PASS**

The CKO contains extensive:

- educational objectives;
- scope;
- clinical knowledge blocks;
- evidence interpretation;
- patient explanation;
- misconceptions;
- key messages;
- questions;
- Knowledge Graph;
- safety boundary.

The Knowledge Passport contains detailed:

- classification;
- runtime use;
- knowledge units;
- evidence maturity;
- governance;
- boundary map;
- safety rules.

The Evidence Package contains:

- evidence hierarchy;
- detailed evidence notes;
- evidence matrix;
- clinical claims;
- consistency review;
- limitations;
- gaps;
- update triggers;
- traceability;
- boundary verification.

The QA Report contains substantive four-layer assessment rather than a checklist-only status.

**No compact Gold treatment identified.**

---

# Clinical Safety Review

## Safety Rule 1

No individual eligibility determination.

**PASS**

## Safety Rule 2

No universal efficacy promise.

**PASS**

## Safety Rule 3

No PCI-only eligibility rule.

**PASS**

## Safety Rule 4

No replacement of systemic therapy.

**PASS**

## Safety Rule 5

No unsupported technical protocol.

**PASS**

## Safety Rule 6

No unsupported individualized prognosis.

**PASS**

---

# Patient Misconception Review

| Misconception | Corrective content present? | Status |
|---|---|---|
| HIPEC is just heated chemotherapy | Yes | PASS |
| Everyone with peritoneal metastases should receive it | Yes | PASS |
| PCI ≤10 guarantees treatment | Yes | PASS |
| HIPEC replaces systemic therapy | Yes | PASS |
| HIPEC always improves OS | Yes | PASS |
| CYTO-CHIP proves universal benefit | Yes | PASS |
| 70% morbidity is universal | Yes | PASS |
| HIPEC compensates for incomplete cytoreduction | Yes | PASS |
| PIPAC = HIPEC | Yes | PASS |
| HIPEC is either standard for everyone or useless | Yes | PASS |

---

# Adjacent PP Overlap Audit

## PP-0224 — Peritoneal Carcinomatosis

### Ownership

Disease-state characterization.

### PP-0226

Treatment modality.

### Result

**PASS — no substantive ownership duplication.**

---

## PP-0225 — Peritoneal Carcinoma as Only Disease

### Ownership

Dedicated peritoneal-only management pathway.

### PP-0226

HIPEC-specific modality and evidence.

### Result

**PASS**

---

## PP-0217 — Response Assessment

### Ownership

Response assessment methodology.

### PP-0226

Uses treatment-response status as selection context.

### Result

**PASS**

---

## PP-0218 — RECIST-based Assessment

### Ownership

RECIST methodology.

### PP-0226

No RECIST methodology.

### Result

**PASS**

---

## PP-0219 — Post-treatment Imaging

### Ownership

Imaging methodology and post-treatment imaging.

### PP-0226

Only high-level restaging context.

### Result

**PASS**

---

## PP-0231 — Treatment-related Toxicity and Supportive Care

### Ownership

Detailed toxicity and supportive management.

### PP-0226

High-level morbidity, mortality and treatment burden.

### Result

**PASS**

---

## PP-0232 — Multidisciplinary Management

### Ownership

MDT workflow.

### PP-0226

Why MDT is required for HIPEC selection.

### Result

**PASS**

---

# Evidence Traceability Audit

## Required

Every major clinical claim must map to a source.

### Verified claims

- HIPEC definition → NCCN.
- PCI ≤10 selected option → NCCN.
- PCI >10 clinical-trial context → NCCN.
- complete cytoreduction → NCCN.
- CYTO-CHIP → NCCN.
- Badgwell phase II → NCCN.
- Yang trial → NCCN.
- GASTRIPEC-I → NCCN.
- PERISCOPE II → NCCN.
- PIPAC investigational → NCCN.

### Assessment

**PASS**

---

# Numerical Evidence Audit

## Verified numerical claims

### CYTO-CHIP

- 277 total;
- 180 HIPEC;
- 97 surgery alone.

### Badgwell

- n=20;
- 70% morbidity;
- 0% mortality;
- median OS 16.1 months;
- 90%, 50%, 28% OS at 1/2/3 years from metastatic diagnosis.

### Yang

- n=68;
- 6.5 vs 11 months;
- P=.046;
- 11.7% vs 14.7% serious AEs;
- P=.839.

### GASTRIPEC-I

- HR .72;
- P=.1647;
- PFS 7.1 vs 3.5 months;
- P=.0472;
- distant metastasis-free survival 10.2 vs 9.2 months;
- P=.0286.

### Assessment

**PASS**

All figures are labeled as study-specific evidence.

---

# Knowledge Graph Audit

## Prerequisites

Present.

## Related

Present.

## Downstream

Present.

## Delegated topics

Present.

### Assessment

**PASS**

Relationships are clinically meaningful and not inserted merely to fill the section.

---

# Evidence Maturity Audit

The package distinguishes:

- Established / guideline-supported;
- Context-dependent;
- Emerging / investigational;
- Not established / excluded.

### Assessment

**PASS**

This is especially important because HIPEC evidence is heterogeneous.

---

# Locked Decision Integrity

## Approved Decision

PP-0226 was approved and locked with the recommended scope:

> specialized treatment-modality package explaining HIPEC, its relationship with cytoreductive surgery, selection principles, evidence, risks, limitations, uncertainty, and patient-facing interpretation.

### Production check

No material reopening or scope expansion detected.

### Assessment

**PASS**

---

# Cross-Artifact Consistency

## CKO

Defines and explains HIPEC.

## Knowledge Passport

Classifies the same treatment-modality knowledge.

## Evidence Package

Supports the same claims with traceable evidence.

## QA Report

Audits the same scope and evidence.

### Boundary consistency

All artifacts use the same ownership model:

**PP-0226 = HIPEC modality**

not:

**PP-0226 = all peritoneal metastatic management.**

### Assessment

**PASS**

---

# Boundary Integrity Audit

## Core

HIPEC modality, evidence, selection context, safety and uncertainty.

**PASS**

## Supporting

Necessary contextual concepts without taking ownership from adjacent PPs.

**PASS**

## Explicitly Excluded

Detailed technical and individualized material excluded.

**PASS**

## Delegated-to PP

Adjacent ownership identified.

**PASS**

---

# Package Integrity

Expected files:

- `01_CKO.md`
- `02_KNOWLEDGE_PASSPORT.md`
- `03_PRIMARY_EVIDENCE_PACKAGE.md`
- `04_QA_REPORT.md`

Expected package:

**PP-0226_HIPEC_GOLD_v1.0.0.zip**

### Assessment

**PASS**

---

# Final QA Matrix

| QA Dimension | Status |
|---|---|
| Content QA | PASS |
| Clinical QA | PASS |
| Educational QA | PASS |
| Governance QA | PASS |
| Clinical Safety Review | PASS |
| Patient Misconception Review | PASS |
| Adjacent PP Overlap Audit | PASS |
| Evidence Traceability Audit | PASS |
| Numerical Evidence Audit | PASS |
| Knowledge Graph Audit | PASS |
| Gold Depth Integrity Review | PASS |
| Source-First Audit | PASS |
| Locked Decision Integrity | PASS |
| Cross-artifact Consistency | PASS |
| Boundary Integrity | PASS |
| Package Integrity | PASS |

---

# Final QA Status

# PASS — GOLD — READY FOR INTEGRATION

---

# Revision History

| Version | Date | Summary |
|---|---|---|
| 1.0.0 | 2026-08-09 | Initial Gold QA after approved PP-0226 Decision Batch |
